Raherison, Chantal http://orcid.org/0000-0003-0015-2883
Ouaalaya, El-Hassane
Bernady, Alain
Casteigt, Julien
Nocent-Eijnani, Cecilia
Falque, Laurent
Le Guillou, Frédéric
Nguyen, Laurent
Ozier, Annaig
Molimard, Mathieu
Funding for this research was provided by:
Fondation Bordeaux Université
Article History
Received: 7 February 2018
Accepted: 5 July 2018
First Online: 16 July 2018
Ethics approval and consent to participate
: The CNIL (National Data Protection and Privacy Commission) and the CCTIRS (Advisory Committee for Data Processing in Health Research) approved the study, and informed verbal consent was obtained before enrollment. The authors had asked the local ethics committee for feedback regarding the need for ethical clearance for such a retrospective analysis, and were advised that this was not warranted.
: Not applicable.
: Dr. Raherison reports grants from Bordeaux University Foundation, during the conduct of the study; personal fees from Astra Zeneca, personal fees from Chiesi, personal fees from ALK, personal fees from Boehringer Ingelheim, personal fees from Glaxo SmithKline, personal fees from MundiPharma, personal fees from Novartis, outside the submitted work; Dr. Nocent-Eijnani has nothing to disclose.Dr. Molimard reports personal fee from the University of Bordeaux, during the conduct of the study, other from Novartis Pharma, GSK, MundiPharma outside the submitted work. Dr. Nguyen has nothing to disclose. Dr. Falque has nothing to disclose. Dr. Casteigt has nothing to disclose. Dr. Le Guillou has nothing to disclose. Dr. Ozier has nothing to disclose. Dr. Bernady has nothing to disclose. Mr. Ouaalaya has nothing to disclose.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.